Zika virus and its implications on cord blood banking and transplantation

Transfusion. 2020 May;60(5):889-891. doi: 10.1111/trf.15771. Epub 2020 Mar 24.

Abstract

Umbilical cord blood is an important cellular therapy product used for hematopoietic stem cell transplantation, but the US Food and Drug Administration guidance regarding donor screening to reduce the risk of Zika transmission has decreased the number of licensed, eligible cord blood units available for transplantation. There is a crucial need for updated travel risk assessment for Zika virus transmission, validated screening tests for Zika virus in umbilical cord blood, and further research on Zika virus transmissibility due to umbilical cord blood products to ensure that umbilical cord blood and related tissues are safe and available for transplantation.

Publication types

  • Review

MeSH terms

  • Blood Banking* / methods
  • Blood Banks* / organization & administration
  • Blood Banks* / standards
  • Cord Blood Stem Cell Transplantation* / adverse effects
  • Cord Blood Stem Cell Transplantation* / methods
  • Cord Blood Stem Cell Transplantation* / standards
  • Donor Selection* / organization & administration
  • Donor Selection* / standards
  • Female
  • Fetal Blood / transplantation
  • Fetal Blood / virology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / methods
  • Hematopoietic Stem Cell Transplantation* / standards
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / statistics & numerical data
  • Male
  • Pregnancy
  • Pregnancy Complications, Infectious / blood
  • Pregnancy Complications, Infectious / virology
  • Risk Assessment
  • Zika Virus / physiology
  • Zika Virus Infection / blood*
  • Zika Virus Infection / epidemiology*
  • Zika Virus Infection / transmission